| Autor: |
Abo-Rady M; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany., Bellmann J; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany., Glatza M; Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany., Marrone L; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany., Reinhardt L; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany.; Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany., Tena S; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany., Sterneckert J; Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Dresden, Germany. jared.sterneckert@tu-dresden.de. |
| Abstrakt: |
High-throughput phenotypic screening enables the identification of new therapeutic targets even when the molecular mechanism underlying the disease is unknown. In the case of neurodegenerative disease, there is a dire need to identify new targets that can ameliorate, halt, or reverse degeneration. Stem cell-based disease models are particularly powerful tools for phenotypic screening because they use the same cell type affected in patients. Here, we describe the expansion of mouse stem cells and human induced pluripotent stem cells as well as the differentiation of these cells into neural lineages that, when exposed to neuroinflammatory stress, can be used for compound screening followed by hit identification, validation, and target deconvolution. |
